Abstract
The complexity of diabetes pathogenesis and the need for lifelong therapy necessitate the search for safe and effective additio­nal means to support metabolic control. Nutraceuticals with proven hypoglycemic activity is a promising direction for this additional component. Given the multifactorial nature of diabetes, the use of the dietary supplement, comprising plant-derived components, chro­mium picolinate and vitamin D, addresses the main pathogenetic links of the disease by modulating key mechanisms such as postprandial glycemia, insulin secretion, insulin resistance, and inflammatory processes. Clinical observations demonstrated its favorable safety profile when used at standard dosages as an adjunct to conventional therapy, with no significant adverse events or glycemic fluctuations reported. Nevertheless, to establish definitive evidence regarding its efficacy and long-term safety, larger-scale and exten­ded-duration studies are needed, including assessments of glycated hemoglobin, biochemical markers, and anthropometric parameters.

This publication has 15 references indexed in Scilit: